[{"id":"25913702-5043-4c47-af74-0e62f5ede59f","acronym":"WU-KONG15","url":"https://clinicaltrials.gov/study/NCT05559645","created_at":"2022-09-29T15:56:55.600Z","updated_at":"2024-07-02T16:35:00.588Z","phase":"","brief_title":"Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)","source_id_and_acronym":"NCT05559645 - WU-KONG15","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-29"},{"id":"e9b64c13-8122-4ab9-9ffd-428aaa84b68b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668988","created_at":"2022-12-30T14:58:35.324Z","updated_at":"2024-07-02T16:35:01.726Z","phase":"Phase 3","brief_title":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","source_id_and_acronym":"NCT05668988","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Zegfrovy (sunvozertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-05-23"},{"id":"0f37c89c-39bf-456d-8d8e-0fef0fe7675f","acronym":"WK-KONG1","url":"https://clinicaltrials.gov/study/NCT03974022","created_at":"2021-01-18T19:32:51.357Z","updated_at":"2024-07-02T16:35:03.473Z","phase":"Phase 1/2","brief_title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","source_id_and_acronym":"NCT03974022 - WK-KONG1","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-05-15"},{"id":"f3ef5fc9-10a5-4e93-ba58-4c7f400c5ab7","acronym":"WU-KONG29","url":"https://clinicaltrials.gov/study/NCT06276283","created_at":"2024-02-23T17:27:29.366Z","updated_at":"2024-07-02T16:35:17.781Z","phase":"Phase 2","brief_title":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","source_id_and_acronym":"NCT06276283 - WU-KONG29","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Zegfrovy (sunvozertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-23"},{"id":"c984142a-7d0e-4aa0-a11f-16b85213c91e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05926180","created_at":"2023-07-03T17:09:22.764Z","updated_at":"2024-07-02T16:35:37.666Z","phase":"Phase 1","brief_title":"Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)","source_id_and_acronym":"NCT05926180","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/31/2023","start_date":" 07/31/2023","primary_txt":" Primary completion: 08/19/2024","primary_completion_date":" 08/19/2024","study_txt":" Completion: 08/19/2024","study_completion_date":" 08/19/2024","last_update_posted":"2023-09-08"},{"id":"47617064-b1e1-478e-9d0c-5d43f28e597b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05712902","created_at":"2023-02-06T16:02:53.976Z","updated_at":"2024-07-02T16:35:56.375Z","phase":"Phase 2","brief_title":"DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation","source_id_and_acronym":"NCT05712902","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 10/17/2022","primary_completion_date":" 10/17/2022","study_txt":" Completion: 05/06/2024","study_completion_date":" 05/06/2024","last_update_posted":"2023-02-06"}]